The FDA's Pharmaceutical Compounding Advisory Committee voted to add six unapproved peptides to the list of substances that compounding pharmacies can use, even though FDA scientists recommended against all of them due to limited evidence of safety and effectiveness. While the vote is only advisory and must still go through formal rulemaking, experts warn it could give patients the false impression that these untested compounds are FDA-approved and accelerate their use through wellness clinics and online platforms.

Why Is This Decision Controversial?

The decision comes at a troubling moment. A woman in New York died after receiving an injection of NAD+, an unapproved drug, at a Bronx wellness center from someone accused of practicing medicine without a license. NAD+ is not a peptide, but it can be prepared by compounding pharmacies under the same regulatory framework being expanded.

Safety advocates argue that broadening access to untested compounds bypasses the rigorous clinical testing that FDA-approved drugs undergo. The Partnership for Safe Medicines, which opposed the panel's decision, emphasized that compounding should not become a workaround for the FDA approval process. The organization warned that the vote could legitimize compounds lacking adequate clinical evidence and increase the spread of potentially unsafe products through wellness clinics, medical spas, and online platforms.

"Compounding shouldn't be used as an end run around the safety assurances of the FDA approval process," stated Shabbir Imber Safdar, Executive Director of the Partnership for Safe Medicines.

Shabbir Imber Safdar, Executive Director, Partnership for Safe Medicines

What Are the Real-World Problems With Compounding Oversight?

A secret shopper study of 75 weight loss clinics and medical spas in two states revealed troubling patterns even after weight loss drug shortages ended. Researchers found that over half of the clinics offered compounded variations of weight loss drugs combined with B vitamins, while smaller percentages offered levocarnitine and glycine. The study also highlighted licensing issues and disciplinary actions among many of the locations visited.

The FDA has also taken enforcement action against manufacturers supplying these compounding pharmacies. The agency issued warning letters to multiple facilities for serious quality control failures, including:

• Mislabeled Materials: An Indian API (active pharmaceutical ingredient) manufacturer knowingly accepted deliberately mislabeled raw materials to bypass licensing requirements and failed to perform required identity testing.
• Data Integrity Failures: Multiple facilities were cited for undocumented laboratory data, inadequate process validation, poor quality oversight, and insufficient stability testing.
• Cross-Contamination Risks: Inadequate equipment cleaning and cleaning validation practices increased the risk of cross-contamination between products, and unvalidated laboratory testing methods failed to detect impurities.

These enforcement actions underscore a broader problem: the supply chain for compounding ingredients lacks the rigorous oversight that FDA-approved pharmaceutical manufacturing requires.

How to Protect Yourself When Considering Compounded Treatments

• Verify FDA Approval: Ask your healthcare provider whether a treatment is FDA-approved. If a compound is described as "for research purposes only" or is being prepared by a compounding pharmacy rather than a pharmaceutical manufacturer, it has not undergone the same safety testing.
• Check Pharmacy Credentials: Confirm that any compounding pharmacy you use is licensed and has no disciplinary actions. You can verify this through your state's pharmacy board website.
• Get Clinical Evidence: Request information about clinical studies supporting the treatment. Legitimate therapies have published research in peer-reviewed journals, not just testimonials or marketing claims.
• Consult Your Doctor: Do not rely solely on wellness clinics or medical spas for medical advice. A licensed physician should evaluate whether a treatment is appropriate for your specific health condition.

The FDA panel's decision reflects a broader tension in supplement and compounding regulation. While compounding pharmacies serve an important role in preparing customized medications for patients with specific needs, the expansion of access to unapproved substances raises questions about whether patient safety is being adequately protected. The tragic death in New York and the enforcement actions against manufacturers suggest that stronger oversight, not broader access, may be what patients actually need.